Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro ...

StockNews.com lowered shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research ...

Stay informed and make well-informed decisions with our Ratings Table. Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals ...

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 6.6% year on year to $657.3 million. The company expects ...

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. Globus Medical beat analysts’ revenue expectations by 3.7% ...

Highlights,Globus Medical specializes in innovative medical devices for musculoskeletal disorders.,The company reported strong earnings, surpassing revenue expectations.,Continuous product development ...

The medical device company posted revenue of $657.3 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $644.3 million. Globus Medical expects full ...

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...